SCHEDULE 13G/A: Syncona Entities Maintain Significant Stake in Autolus Therapeutics, Disclosing 10.8% Beneficial Ownership
Beneficial Ownership Disclosure
Syncona Portfolio Limited and related entities, including Syncona Holdings, Syncona Investment Management, Syncona Limited, and key individuals, have filed an amended Schedule 13G, reaffirming their collective beneficial ownership of 10.8% in Autolus Therapeutics plc.
Summary
- Syncona Portfolio Limited, Syncona Holdings Limited, Syncona Investment Management Limited, Syncona Limited, and individuals Roel Bulthuis, Christopher Hollowood, and Kenneth Galbraith collectively reported beneficial ownership of 28,821,053 Ordinary Shares of Autolus Therapeutics plc.
- This aggregate amount represents 10.8% of Autolus Therapeutics plc's outstanding Ordinary Shares.
- The ownership consists of 12,180,333 ordinary shares and 16,640,720 American Depositary Shares (ADSs), with each ADS representing one ordinary share, held directly by Syncona Portfolio Limited.
- The percentage of class is based on 266,128,900 Ordinary Shares outstanding, as reported in Autolus Therapeutics plc's Form 10-K filed with the SEC on March 20, 2025.
- The filing is an Amendment No. 8 to Schedule 13G, indicating a continuation or update of previously reported ownership, with the event date requiring filing being March 31, 2025.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects. It is a routine regulatory filing.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of significant beneficial ownership in a publicly traded biotechnology company, Autolus Therapeutics plc, by a group of investment entities and individuals associated with Syncona. Such disclosures are common in the investment landscape, particularly for companies with significant institutional backing, and do not inherently indicate new strategic shifts or financial performance within the biotechnology sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception of stability and institutional confidence.
Key Dates
| Date | Description |
|---|---|
| 03/20/2025 | Date Autolus Therapeutics plc's Form 10-K was filed with the SEC, reporting 266,128,900 Ordinary Shares outstanding. |
| 03/31/2025 | Date of event which required the filing of this Schedule 13G statement. |
| 05/07/2025 | Signature date for all reporting persons on the Schedule 13G. |
Keywords
Autolus Therapeutics, Syncona Portfolio Limited, Syncona Holdings Limited, Syncona Investment Management Limited, Syncona Limited, Beneficial Ownership, Schedule 13G, SEC Filing, Ordinary Shares, American Depositary Shares, Biotechnology, Pharmaceuticals, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.